Mobile Program Tests Support for Diabetes Stress in Families of School-Age Children
Tests a phone-based program easing diabetes stress in families of children with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families
Key facts
- Where
- Jacksonville and Kansas City, United StatesSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 65 years old?
Source: NCT05268250, who can take part
Where in United States
- Nemours Children's HealthJacksonville, United StatesTaking people
- Children's Mercy Kansas CityKansas City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Nemours Children's Clinic
- Trial code
- NCT05268250
- Record updated
- 1 September 2026
- Original description
This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age children with T1D (called Remedy to Diabetes Distress [R2D2]) and to test the initial efficacy of R2D2 to reduce diabetes distress to improve children's glycemic control.Read full original descriptionShow less
Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families
This R01 is in response to RFA-DK-19-021, Treating Diabetes Distress to Improve Glycemic Outcomes in Type 1 Diabetes. The objective is to test the feasibility and acceptability of a novel, practical, and potentially scalable screen to treat program for diabetes distress in families of school-age children with T1D (called Remedy to Diabetes Distress [R2D2]) and to test the initial efficacy of R2D2 to reduce diabetes distress to improve children's glycemic control.
Inclusion: child age between 8-12 years, physician confirmed T1D diagnosis,; either the child or the parent or both the child and parent report diabetes distress levels at or above clinical cut-points,; child is on an intensive insulin regimen (pump or MDI).
Exclusion: children on a conventional insulin regimen, children and/or parents who do not report diabetes distress levels at or above the clinical cut-points,; children who have an allergy or sensitivity to the adhesive and/or skin preparation used for CGM, children with a comorbid chronic condition (e.g., renal disease),; children and parents who do not speak English.